A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
Site Search
Showing 1 - 10 of 18 results
News
|
|
3 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
2 min read
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
News
|
|
2 min read
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
News
|
|
3 min read
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Press Release
|
|
4 min read
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
Press Release
|
|
6 min read